Why the study?
Although experimental studies indicate the kynurenine pathway regulates vascular inflammation and atherogenesis, its role in human atherosclerosis remains incomplete.
Is a deviation in the kynurenine pathway associated with aggravated atherosclerotic disease and vascular inflammation?
Is a deviation in the kynurenine pathway associated with aggravated atherosclerotic disease and vascular inflammation?
Reduced kynurenic acid production in the kynurenine pathway is associated with unstable atherosclerotic disease and regulates vascular inflammation via AhR signaling.
Should not yet change atherosclerosis management; animal data leave open kynurenic acid modulation as a therapeutic target.
No takes yet. Share an insight, caveat, or question.
Baumgartner et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: